Cargando…
1600. Closing the gap on moxifloxacin breakpoints for Stenotrophomonas maltophilia
BACKGROUND: Moxifloxacin (MOX) has in vitro activity against Enterobacterales and Stenotrophomonas maltophilia (SM). Although MOX commonly displays lower minimum inhibitory concentration (MIC)(50/90) values against SM when compared to levofloxacin, there are currently no established MOX breakpoints...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776320/ http://dx.doi.org/10.1093/ofid/ofaa439.1780 |